Abstract The molecular basis of metronidazole resistance has been examined in anaerobic bacteria, such as Bacteroides, Clostridium, and Helicobacter, and anaerobic parasitic protists such as Giardia, Entamoeba, and trichomonads.A variety of enzymatic and cellular alterations have been shown to correlate with metronidazole susceptibility in these pathogens; however, a common theme has been revealed. Resistant cells are typically deficient in drug activation.The frequent correlation between metronidazole resistance and ineffective drug activation suggests that drug resistance is the result of modification of proteins involved in drug activation.
INTRODUCTION
etronidazole (commonly known as Flagyl) is a 5-nitroimidazole compound used to treat a wide variety of infections caused by pathogenic bacteria and protists, such as Helicobacter, Clostridium, Bacteroides (bacteria), Trichomonas, Entamoeba, and Giardia (human-infective parasitic protists) and Tritrichomonas (a cattle-infective parasitic protist). Metronidazole is administered in an inactive form and becomes activated in either the cytoplasm (in the case of infections caused by bacteria and Entamoeba and Giardia) or in a specialized organelle called the hydrogenosome (in Trichomonas and Tritrichomonas). Clinical resistant strains of each of these pathogens have been described, but little is known about the molecular basis for metronidazole resistance.
SELECTIVE ACTIVATION OF METRONIDAZOLE TO FREE-RADICAL, CYTOTOXIC FORMS
The cytotoxic selectivity of metronidazole results from the necessity of the drug to be reduced to an active cytotoxic form. The nitro group of metronidazole is reduced via metabolic pathways of low redox potential. The absence of electron-transport proteins with sufficiently negative redox potential to allow drug activation renders the drug ineffective in aerobic cells. This selective cytotoxicity of metronidazole relies on biochemical properties of these pathogens that are lacking in the aerobic cells of the eukaryotic hosts that harbor them.
Metronidazole is administered in an inactive form and enters the cell by passive diffusion (Fig. 1) . 1, 2 In anaerobic cells, conversion of the drug from inactive to active form leads to further uptake of the inactive form.Thus, the rate of intracellular activation is important as it affects drug uptake via a concentration gradient.
In this review article, we present an overview of our current understanding of the mechanisms underlying metronidazole resistance in several bacterial and protozoal pathogens (Table 1) .
METRONIDAZOLE RESISTANCE IN BACTERIA
It has long been recognized that metronidazole is an effective antimicrobial against many types of anaerobic bacterial pathogens, including Clostridium and Bacteroides. In recent years, it has been observed that this drug is also effective against a variety of microaerophilic bacteria such as Helicobacter pylori and Campylobacter spp.. With its increased use against microaerophiles, resistant isolates of these different bacteria have emerged.
Bacteroides and Clostridium
Genes implicated in 5-nitroimidazole resistance in Bacteroides have been isolated from several species, including B. vulgatus and B. fragilis. [3] [4] [5] Most of these genes, called nim, are found on low-copy number plasmids, although one gene, nimB from B. fragilis, has been mapped to the chromosome. The transfer of nim genes to susceptible recipients has been shown to increase metronidazole resistance [3] [4] [5] and these loci are currently described as undefined 5-nitroimidazole resistance determinants of unknown origin. The function of nim genes is unknown. Haggoud and colleagues 6 examined the hydrophobicity profiles of the putative nim gene products; no predictable membranespanning region was identified, as one might expect if the gene product served as a membrane transporter. Recently, it has been suggested that nim genes may encode a 5-nitroimidazole reductase that could convert 5-nitroimidazoles to a non-toxic amino derivative, eliminating its cytotoxic effects. 7 The relevance of nim genes in metronidazole susceptibility in Bacteroides requires further studies.
289
Studies on metronidazole resistance in Clostridium have provided biochemical evidence that the bidirectional hydrogenase (hydrogenase 1) of C. pasteuranium plays a critical enzymatic role in the reduction of metronidazole via a ferredoxin-linked mechanism. 8, 9 Genes controlling the activation of metronidazole in C. acetobutylicum have also been identified. Among the genes shown to confer high levels of sensitivity to metronidazole were those encoding a flavodoxin and a hydrogenase. 10 These proteins could serve as electron donors to metronidazole for drug activation. Along these lines, flavodoxins from Clostridium have been shown to be capable of replacing ferredoxins as electron carriers.
10

Helicobacter pylori
Helicobacter pylori is a spiral gram-negative bacterium that was first isolated in 1982 from the gastric mucosa of a patient inflicted with gastritis and peptic ulceration. 11 Since then, there has been increasing evidence that H. pylori plays an important role in duodenal ulceration. 12 Metronidazole has been used in multiple antimicrobial therapeutic strategies to eradicate H. pylori. Interest in metronidazole resistance in H. pylori has increased with the emergence of resistant isolates in developing countries and some 10-30% of strains from the US and Western Europe. 13 Proposed mechanisms of resistance in H. pylori include: (1) decreased drug uptake or active efflux; (2) deficiency in metronidazole activation or modification; (3) target modification or loss; and (4) and increased DNA repair or oxygen scavenging capabilities. 14 The inactivation of recA, a gene needed for generalized DNA repair and recombination, enhanced the susceptibility of H. pylori to metronidazole. 15 Expression of a cloned recA gene from a metronidazole resistant strain seemed to increase the level of resistance in E. coli. 16 Early biochemical studies on resistant isolates focused on the metabolic enzymes of H. pylori; specifically on pyruvate:ferredoxin/flavodoxin oxidoreductase (POR) and α-ketoglutarate oxidoreductase (KOR).
14 The premise for this work was based on studies in anaerobic protists which showed that POR activity was decreased in resistant strains (see below). Studies by Hoffman and colleagues 14 demonstrated that in H. pylori POR and KOR activities in resistant strains were repressed in cells grown in the presence of the drug, but not in the absence of the drug. These findings suggested a model where metronidazole could regulate the activity of the metabolic enzymes POR and KOR in H. pylori; the presence of the drug would down-regulate the activity of the enzymes, and vice versa. Whether this regulatory effect on enzyme activity by metronidazole was the primary cause of resistance or was a secondary manifestation of another mutation was not demonstrated.
Recently, work by Hoffman and colleagues 17 showed that inactivation of an H. pylori gene encoding an oxygeninsensitive NADPH nitroreductase, called rdxA (designated HP0954 in the entire genome sequence), 18 is the cause of naturally acquired metronidazole resistance in H. pylori.The 
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Deficiencies in hydrogenosomal proteins involved in drug activation and organellar function? (Cerkasovova et al. 1984) strategy used to identify the metronidazole-resistance determinant in H. pylori extended from an earlier observation that H. pylori were naturally competent for uptake of chromosomal DNA, and that DNA from resistant clinical strains could transform sensitive strains to resistant ones. 19 It was not clear whether the resistance determinant was due to mutations in the genome or the acquisition of an additional gene.To overcome this problem, a cosmid library was first constructed with genomic DNA from a resistant strain; cosmid DNAs were then tested for their ability to transform metronidazole-sensitive H.pylori to a metronidazole-resistant phenotype. Open reading frames identified included a gene with protein-level homology to classical oxygen-insensitive NADPH nitroreductases of several other Gram-negative bacteria. 17 PCR amplification and sequencing of the corresponding segment from the metronidazole sensitive strain revealed an ORF that was 14 codons longer at the 3′ end. This indicates that metronidazole resistance in H. pylori is caused by inactivation of rdxA, which in the resistant strain examined occurred by a nonsense mutation that resulted in a truncated rdxA protein.
To further explore the possibility that alterations in rdxA could confer resistance to metronidazole, rdxA was expressed in E. coli, which is known to be metronidazole resistant.The expression of rdxA in E. coli rendered the cells susceptible to metronidazole. Moreover, allelic exchange mutagenesis and complementation demonstrated that rdxA inactivation is sufficient for metronidazole resistance. 17 Interestingly, it was observed that growth of rdxA mutants in metronidazole containing medium also resulted in the disappearance of POR activity. Furthermore, during growth in metronidazole-free medium, this mutant strain exhibited only half as much POR activity as its parental strain. This suggests that mutations in rdxA may indirectly affect the level of POR activity. This study establishes that null mutations in just a single gene, rdxA, are responsible for metronidazole resistance in H. pylori.
METRONIDAZOLE RESISTANCE IN PARASITIC PROTISTS
In addition to treating bacterial pathogens, metronidazole is used to treat infections with anaerobic protozoan parasites, including Trichomonas, Tritrichomonas, Giardia and Entamoeba.
Giardia lamblia and Entamoeba histolytica
Treatment-refractory cases of patients with persistent giardiasis have been documented 20 and these resistant isolates, when examined at the biochemical level, appear to have defective pyruvate:ferredoxin oxidoreductase (PFO) activity. The components of the electron transport pathway involved in metronidazole activation have not yet been completely defined in this parasite, but two of the crucial components, PFO and ferredoxin (Fd), have been purified. [21] [22] [23] Giardia PFO, one of two major cytosolic 2-oxoacid oxidoreductases, transfers electrons to Giardia ferredoxin (Fd 1) with simultaneous reduction of metronidazole. 23 Ferredoxins from C. pasteurianum and T. foetus are also able to act as acceptors of electrons from purified Giardia PFO.
The purified Giardia ferredoxin has likewise been shown to be capable of activating metronidazole in vitro. 22 Given the role of ferredoxin and PFO in electron transport pathways in Giardia, an analysis of their expression or activities in drug resistant strains should lend insight into the molecular basis for resistance.Those readers interested in an update on proposed mechanisms of drug resistance in Giardia are encouraged to consult a review article by Upcroft in this journal. 24 Metronidazole resistance in E. histolytica has been described, but the molecular basis of resistance is not clear and has not been studied extensively. Research on drug resistance in E. histolytica has been primarily centered on studying emetine resistance, a drug that is unrelated to the nitroimidazoles. Emetine resistance appears to be modulated by expression of P-glycoproteins, transmembrane proteins that are postulated to pump the drug out of the cell. Overexpression of the E. histolytica P-glycoprotein (Eh pgp1) gene confers emetine resistance. 25 Other P-glycoprotein genes have been cloned from E. histolytica (Eh pgp5 and Eh pgp6) and all three Pgp genes have been shown to be overexpressed in the resistant strain C2. 26 Readers interested in mechanisms of emetine resistance in E. histolytica are encouraged to consult a review article by Orozco and colleagues. 27 With regard to metronidazole resistance, both Fd 28 and PFO 29 genes have been cloned from E. histolytica. Like Giardia, E. histolytica does not possess hydrogenosomes and the activation of metronidazole occurs in the cytoplasm, where the electron-transfer components PFO and Fd are located.The possible role of these proteins, as well as others of unrelated function, in development of metronidazole resistant strains of E. histolytica is unclear. In light of this, Upcroft and colleagues 30 generated a metronidazole-resistant strain of E. histolytica by prolonged exposure of a susceptible strain to metronidazole in order to examine changes which occur in the development of resistance. Using these isogenic strains, PFO levels and activity were assayed in the resistant and susceptible strains. Using immunofluorescence and immunoblot analysis, it appeared that the levels of PFO were either the same between the two strains, or slightly increased in the resistant cells. Spectrophotometric analysis of PFO activities in resistant and susceptible cells revealed an increased activity in resistant cells. Parallel to these experiments, the activity of iron superoxide dismutase (FeSOD) was analyzed in both strains; and interestingly, there was an increase in FeSOD activity in the resistant cells. Furthermore, another recent study strengthens the potential role of SOD in metronidazole resistant E. histolytica. 31 In this study, metronidazole resistant cells were shown to overexpress FeSOD and have decreased expression of ferredoxin I and flavin reductase. Using transfection techniques, overexpression of FeSOD and peroxiredoxin in sensitive cells gave rise to cells with increased resistance to metronidazole, demonstrating a direct role for these proteins in metronidazole susceptibility. 31 
Trichomonas vaginalis and Tritrichomonas foetus
Trichomonas vaginalis is a flagellated human parasitic protist which infects the urogenital tract. Resistant strains isolated from patients who were refractory to treatment with metronidazole have been described and catalogued with the ATCC. 32 Drug activation in trichomonad parasites is thought to occur via similar metabolic pathways as previously described for E. histolytica and G. lamblia, with the exception that these biochemical pathways are compartmentalized into a specialized organelle called the hydrogenosome. This unusual organelle is the site of carbohydrate metabolism, as well as drug activation. 33 Once the drug has entered the organelle by passive diffusion, the process of activation involves a transfer of a single electron from the hydrogenosomal protein pyruvate:ferredoxin oxidoreductase (PFO) and ferredoxin (Fd) to the nitro group of metronidazole, converting the drug to its cytotoxic form (Fig. 1) . PFO and ferredoxin are part of an electron transfer chain that mediates the oxidation of pyruvate to acetyl-CoA within the hydrogenosome. 34, 35 For the details of metronidazole activation by PFO and ferredoxin, the reader is referred to studies described by Moreno and colleagues 36, 37 and Yarlett and colleagues. [38] [39] [40] Early work on metronidazole resistance in Trichomonas vaginalis using resistant clinical isolate CDC085 and susceptible laboratory strain ATCC30001 suggested two possible hypotheses for resistance: (1) that a defective ferredoxin protein existed in the resistant isolate; or (2) reduced levels of the ferredoxin protein were present in CDC085. 39 With the cloning of the T. vaginalis ferredoxin gene, 41 a detailed molecular analysis of the ferredoxin gene and its expression in sensitive and resistant cells was carried out. Quon et al. 42 were able to demonstrate a strict correlation between altered transcription of the ferredoxin gene and drug resistance in four clinically-resistant strains (including CDC085) when compared to two drug sensitive isolates. Detailed molecular analysis revealed that clinically resistant strains of T. vaginalis have decreased levels of the ferredoxin protein and its mRNA.The reduced levels of protein and mRNA were attributed to reduced transcription of the ferredoxin gene as determined by nuclear run-on assays. 42 These findings strongly correlate metronidazole resistance with altered regulation of ferredoxin gene transcription in clinically resistant strains of T. vaginalis. This reduction in gene transcription results in decreased intracellular levels of ferredoxin, and this, in turn, may limit the ability of the cell to activate metronidazole. However, whether ferredoxin plays a direct role in drug susceptibility is unknown. Mutations in other cellular components could possibly have a 'downstream effect' on the expression of ferredoxin and subsequently affect the susceptibility of the cell to the drug.
The molecular mechanisms underlying metronidazole resistance in trichomonads appear to involve either deficiencies or defects in hydrogenosomal components necessary for drug activation. However, studies on other parasitic protists (such as Entamoeba) suggest a role for the overexpression of a P-glycoprotein in conferring resistance to other drugs, such as emetine, by possibly transporting the drug out of the cell. Whether such transporter proteins play a role in drug resistance in T. vaginalis is not clear. In light of this possibility, a P-glycoprotein-like gene related to members of the ABC (ATP-binding cassette) family of transporter proteins was cloned and characterized from T. vaginalis. 43 This gene (Tvpgp) was found to be present in two copies in all examined drug sensitive T. vaginalis strains. Upon examination of seven clinical resistant strains, overexpression of Tvpgp (2-20 fold) was observed in three strains. Interestingly, in four of the seven drug resistant strains studied, only one copy of Tvpgp was present. No clear correlation between levels of Tvpgp expression and gene copy number was observed. For example, two of three strains that overexpress Tvpgp contained two genes; however, the third strain contained only one gene. Likewise, there is no correlation between levels of Tvpgp expression and levels of drug resistance. It is possible that these genes have point mutations which alter the interaction of the encoded protein with the drug. Alternatively, Tvpgp may not interact with metronidazole. The lack of a consistent relationship between metronidazole resistance and levels of expression of Tvpgp in T. vaginalis is reminiscent of that observed in other drugresistant protists. [44] [45] [46] [47] [48] [49] These observations have led to the suggestion that the P-glycoprotein in parasitic protists may be involved in a general stress response that allows the organism to survive until a specific response is mounted. 47 However, it is impossible to test whether this is the case, as the parental strains which gave rise to these clinicallyresistant isolates are not available. For this reason, we and others have turned to the use of isogenic strains, where resistance was generated in the laboratory to allow one to examine changes that occur during development of resistance and to make comparisons with the drug sensitive parental strain.
Isogenic metronidazole-resistant strains of T. foetus and T. vaginalis have been generated in the laboratory of Kulda and colleagues by continuous challenge of a drug sensitive strain (KV1) with metronidazole over a long period of time until stable resistance lines were present (MR-100) which could grow continuously on high levels of metronidazole. 50, 51 The slow development of cells with increasing levels of stable resistance over time suggests that there is a multi-step process involved in the acquisition of the stable resistant phenotype (cells with intermediate levels of resistance are unstable). The eventual loss of hydrogenosomal activity in highly resistant cells would intuitively involve multiple mutations.
Detailed biochemical analyses of these resistant cells show ablated enzymatic activities of PFO and another hydrogenosomal protein, hydrogenase (HYD), the enzyme which catalyzes formation of molecular hydrogen under anaerobic conditions. 52, 53 More recently, using metronidazole resistant strains generated in a similar fashion to that of Kulda and coworkers, Brown and colleagues have demonstrated a loss of PFO and ferredoxin mRNA in resistant cells. Further analysis of these resistant cells demonstrated alternative pathways for utilizing substrates for energy while circumventing the activation of metronidazole.
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A COMMON THEME
Based on studies of metronidadazole resistance in H. pylori and trichomonad parasites, it appears that lack of drug activation is the primary mechanism of drug resistance in these organisms. Alteration of rdxA in H. pylori would theoretically lead to lowered or no drug activation in resistant cells, although there is no evidence yet for direct activation of metronidazole in these cells by the product of the rdxA gene. In trichomonads, the loss of crucial hydrogenosomal proteins needed for metronidazole activation leads to decreased or no drug activation in resistant isolates. The frequent correlation between metronidazole resistance and inefficient drug activation suggests that this is the level at which drug resistance operates. Whether additional mechanisms also contribute to resistance awaits more detailed studies.
FUTURE DIRECTIONS
The advancement of knowledge of drug resistance in pathogenic bacteria and protists will be greatly enhanced with the complete sequencing of these microbial genomes.The complete genomic sequence of H. pylori has already been reported. 18 The identification of potential components involved in drug resistance is now feasible. Furthermore, there is the possibility of identifying alternative drug targets for clinical cases that are refractory to treatment.
Molecular and cellular studies on the pathogenic protists have lagged behind that of bacteria. Limitations in recombinant DNA technologies, the lack of established genetic systems, and the significantly larger genomes of protists have slowed progress towards determining precise mechanisms for drug resistance. Recent developments of genetic techniques that can be applied to protists should allow definitive identification of alternations that result in drug resistance. [55] [56] [57] [58] [59] [60] [61] [62] [63] 
